+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Nanotechnology-Based Targeted Drug Delivery Systems for Lung Cancer

  • ID: 4612891
  • Book
  • 340 Pages
  • Elsevier Science and Technology
1 of 3

Nanotechnology-based Targeted Drug Delivery Systems for Lung Cancer is an indispensable resource that will help pharmaceutical scientists and clinical researchers design and develop novel drug delivery systems and devices for the treatment of lung cancer. As recent breakthroughs in nanomedicine are now making it possible to deliver drugs, genes and therapeutic agents to localized areas of disease to maximize clinical benefit, while also limiting unwanted side effects, this book explores promising approaches for the diagnosis and treatment of lung cancer using cutting-edge nanomedical technologies. Topics discussed include polymeric nanoparticles, solid lipid nanoparticles, liposomes, dendrimers, micelles and nanoemulsions.

  • Provides an overview of an array of nanotechnology-based drug delivery systems
  • Examines the design, synthesis and application of different nanocarriers in drug and gene delivery
  • Provides an in-depth understanding of the design of targeted nanotherapeutics and technologies and its implication in various site-specific cancers

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

Note: Product cover images may vary from those shown
2 of 3

1. Introduction: An Overview of the anatomy and physiology of the lung 2. Major Challenges in the Lung Cancer Therapy : Distant Metastasis and Drug Resistance 3. Active Targeting Systems (Ligands) / Receptor overexpressed on lung cancer 4. Polymeric nanoparticles based drug delivery for lung cancer 5. Solid lipid nanoparticles based drug delivery for lung cancer 6. Liposomes and niosomes based drug delivery for lung cancer 7. Dendrimers based drug delivery for lung cancer 8. Micelles based drug delivery for lung cancer 9. Nanoemulsions based drug delivery for lung cancer 10. Nanomedicine-based inhalation treatments for lung cancer 11. Towards development of novel diagnostic nano-imaging platform for lung cancer 12. Hydrogel based drug delivery for lung cancer 13. Quantum dots based drug delivery for lung cancer

Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Kesharwani, Prashant
Dr. Prashant Kesharwani is currently working as Assistant Professor, Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India. He received his doctoral degree in Pharmaceutical Sciences from the Dr H.S. Gour University (Sagar, India) with Prof N.K Jain's group. He is a recipient of several internationally acclaimed awards viz "Ramanujan Fellowship, DST, India-2017”, "Excellence Research Award-2014”, "Young Innovator Award (Gold medal)-2012”, "International Travel Award/Grant from DST (New Delhi), and INSA (CCSTDS, Chennai)-2012”. He has received ICMR Senior Research Fellowship (in PhD) and AICTE Junior Research Fellowship (in M. Pharm.). After his doctorate, he worked as postdoctoral fellows in the Wayne State University, Detroit (Michigan, USA). Dr. Kesharwani subsequently joined the School of Pharmacy, International Medical University (Malaysia) as lecturer in Pharmaceutical Technology. Subsequently he joined Central Drug Research Institute (CDRI), Lucknow as Ramanujan Fellow. An overarching goal of his current research is the development of nano-engineered drug delivery systems for cancer through with prime focus on dendrimer and polymeric nanomicelles mediated drug delivery systems. Dr. Kesharwani is a co-author on more than 120 publications in high impact factor international journals and 4 international books with total citations of more than 3300 (h index is 27 and i-10 index is 65 as per Google Scholar).
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4612891
Adroll
adroll